<DOC>
	<DOCNO>NCT02605447</DOCNO>
	<brief_summary>The EVOLVE Short DAPT Study prospective , multicenter , single-arm study design assess safety 3-month DAPT subject high risk bleed undergoing PCI SYNERGY Stent System .</brief_summary>
	<brief_title>EVOLVE Short DAPT Study</brief_title>
	<detailed_description>The primary objective EVOLVE Short DAPT Study assess safety 3-month dual antiplatelet therapy ( DAPT ) subject high risk bleed undergo percutaneous coronary intervention ( PCI ) SYNERGY Stent System . The study conduct 120 site worldwide United States , Europe , Japan , Brazil plan enrollment approximately 2,000 subject . Clinical follow-up require following time point : 3 month , 6 month , 12 month 15 month post index procedure . Subjects must treat one follow P2Y12 inhibitor ( clopidogrel , prasugrel , ticagrelor ) 3 month follow index procedure . Subjects must treat aspirin duration trial . The minimum daily maintenance dose aspirin 75-100 mg . Note : For subject take anticoagulation , aspirin 0-3 month require ( investigator discretion ) . Subjects eligible discontinuation P2Y12 inhibitor 3 month meet follow criterion : subject treat 3 month study require antiplatelet therapy post index procedure ; subject free event ( stroke , MI , PCI , coronary artery bypass graft [ CABG ] , stent thrombosis ) index procedure 3 month visit . Subjects eligible discontinuation P2Y12 inhibitor 3 month follow criterion meet : subject experience stroke , MI , PCI , CABG and/or stent thrombosis , 0-3 month period ( date index procedure date 3-month follow-up visit ) ; subject non-compliant study require antiplatelet therapy 0-3 month period ( date index procedure date 3-month follow-up visit ) ; subject judge inappropriate discontinuation P2Y12 inhibitor use 3 month due another condition require chronic P2Y12 inhibitor use . All enrolled subject receive SYNERGY stent must follow milestone 15-months , regardless eligibility discontinue P2Y12 inhibitor . Following 3-month milestone , subject experience MI stent thrombosis event treat per investigator 's discretion follow 15-month visit .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<criteria>1 . Subject consider high risk bleeding , define meet one follow criterion time enrollment : ≥ 75 year age , opinion investigator , risk major bleed associate &gt; 3 month DAPT outweigh benefit , need chronic lifelong anticoagulation therapy , history major bleeding ( severe/life threaten moderate bleeding base GUSTO classification ) within 12 month index procedure , history stroke ( ischemic hemorrhagic ) , renal insufficiency ( creatinine ≥2.0 mg/dl ) failure ( dialysis dependent ) , platelet count ≤100,000/μL 2 . Subject must least 18 year age 3 . Subject must implantation least one SYNERGY stent within precede 3 calendar day 4 . Subject must able take study require antiplatelet therapy ( require per protocol ) 5 . Subject willing comply protocol requirement , include agreement stop take P2Y12 inhibitor 3month milestone , eligible per protocol 6 . Subject ( legal guardian ) understand trial requirement treatment procedure provide write informed consent studyspecific procedure perform 7 . For subject le 20 year age enrol Japanese site , subject/ subject 's legal representative must provide write informed consent studyspecific test procedure perform 1 . Subject indication index procedure acute ST elevation MI ( STEMI ) 2 . Subject indication index procedure Non ST elevation MI ( NSTEMI ) , base 3rd Universal MI definition 3 . Subject treatment another coronary stent , SYNERGY , index procedure 4 . Subject plan staged procedure . ( Note : Planned stag procedure allow perform within 7 day SYNERGY stent ) . 5 . Subject know allergy contrast ( adequately premedicated ) , SYNERGY stent system protocolrequired concomitant medication ( e.g. , everolimus structurally related compound , polymer individual component , P2Y12 inhibitor aspirin ) 6 . Subject implantation drugeluting stent within 9 month prior index procedure 7 . Subject previously treat time intravascular brachytherapy 8 . Subject active peptic ulcer active gastrointestinal ( GI ) bleed 9 . Subject participate investigational drug device clinical trial reach primary endpoint ( Note : registry , observational , data collection study exclusionary ) 10 . Subject intend participate investigational drug device clinical trial within 15 month follow index procedure ( Note : registry , observational , data collection study exclusionary ) 11 . Subject judged inappropriate discontinuation P2Y12 inhibitor use 3 month , due another condition require chronic P2Y12 inhibitor use 12 . Subject plan surgery procedure necessitate discontinuation P2Y12 inhibitor within 3 month follow index procedure 13 . Subject woman pregnant nursing 14 . Subject current medical condition life expectancy le 15 month 15 . Target lesion ( ) locate leave main 16 . Target lesion ( ) locate within 3 mm origin leave anterior descending ( LAD ) coronary artery leave circumflex ( LCx ) coronary artery visual estimate 17 . Subject unprotected leave main coronary artery disease ( &gt; 50 % diameter stenosis ) 18 . Planned treatment 3 lesion 19 . Planned treatment lesion 2 major epicardial vessel 20 . Target lesion ( ) treat involve complex bifurcation ( i.e . bifurcation lesion require treatment one stent ) 21 . Target lesion ( ) restenotic previous stent implantation 22 . Target lesion ( ) locate within saphenous vein graft arterial graft 23 . Target lesion ( ) TIMI flow 0 ( total occlusion ) TIMI flow 1 prior guide wire cross 24 . Thrombus , possible thrombus , present target vessel ( visual estimate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>